<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31796853</article-id><article-id pub-id-type="pmc">6890777</article-id><article-id pub-id-type="publisher-id">54807</article-id><article-id pub-id-type="doi">10.1038/s41598-019-54807-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Loss of the serine protease HTRA1 impairs smooth muscle cells maturation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Klose</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Prinz</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tetzlaff</surname><given-names>Fabian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Weis</surname><given-names>Eva-Maria</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Moll</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodriguez-Vita</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oka</surname><given-names>Chio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Korff</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fischer</surname><given-names>Andreas</given-names></name><address><email>a.fischer@dkfz.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution>Division Vascular Signaling and Cancer (A270), </institution><institution>German Cancer Research Center, </institution></institution-wrap>69120 Heidelberg, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2190 4373</institution-id><institution-id institution-id-type="GRID">grid.7700.0</institution-id><institution>European Center for Angioscience (ECAS), </institution><institution>Medical Faculty Mannheim, Heidelberg University, </institution></institution-wrap>68167 Mannheim, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9227 2257</institution-id><institution-id institution-id-type="GRID">grid.260493.a</institution-id><institution>Laboratory of Gene Function in Animals, </institution><institution>Nara Institute of Science and Technology, </institution></institution-wrap>8916-5 Takayama, Ikoma, Nara 630-0192 Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2190 4373</institution-id><institution-id institution-id-type="GRID">grid.7700.0</institution-id><institution>Institute of Physiology and Pathophysiology, </institution><institution>Heidelberg University, </institution></institution-wrap>69120 Heidelberg, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0328 4908</institution-id><institution-id institution-id-type="GRID">grid.5253.1</institution-id><institution>Medical Clinic I, Endocrinology and Clinical Chemistry, </institution><institution>Heidelberg University Hospital, </institution></institution-wrap>69120 Heidelberg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>9</volume><elocation-id>18224</elocation-id><history><date date-type="received"><day>31</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Vascular smooth muscle cell (VSMC) dysfunction is a hallmark of small vessel disease, a common cause of stroke and dementia. Two of the most frequently mutated genes in familial small vessel disease are <italic>HTRA1</italic> and <italic>NOTCH3</italic>. The protease HTRA1 cleaves the NOTCH3 ligand JAG1 implying a mechanistic link between HTRA1 and Notch signaling. Here we report that HTRA1 is essential for VSMC differentiation into the contractile phenotype. Mechanistically, loss of HTRA1 increased JAG1 protein levels and NOTCH3 signaling activity in VSMC. In addition, the loss of HTRA1 enhanced TGF&#x003b2;-SMAD2/3 signaling activity. Activation of either NOTCH3 or TGF&#x003b2; signaling resulted in increased transcription of the <italic>HES</italic> and <italic>HEY</italic> transcriptional repressors and promoted the contractile VSMC phenotype. However, their combined over-activation led to an additive accumulation of HES and HEY proteins, which repressed the expression of contractile VSMC marker genes. As a result, VSMC adopted an immature phenotype with impaired arterial vasoconstriction in Htra1-deficient mice. These data demonstrate an essential role of HTRA1 in vascular maturation and homeostasis by controlling Notch and TGF&#x003b2; signaling.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cardiovascular diseases</kwd><kwd>Molecular medicine</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft (German Research Foundation)</institution></institution-wrap></funding-source><award-id>SFB 1366</award-id><principal-award-recipient><name><surname>Fischer</surname><given-names>Andreas</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003390</institution-id><institution>Fritz Thyssen Stiftung (Fritz Thyssen Foundation)</institution></institution-wrap></funding-source><award-id>10.13.1.160</award-id><principal-award-recipient><name><surname>Fischer</surname><given-names>Andreas</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Familial small vessel disease is a major cause of stroke and dementia under the age of 60 with <italic>NOTCH3</italic> and <italic>HTRA1</italic> being two of the most frequently mutated genes<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In addition, several loss-of-function mutations in <italic>HTRA1</italic> are causative for cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL syndrome)<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, which is similar to dominantly inherited CADASIL syndrome caused by neomorphic <italic>NOTCH3</italic> mutations<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. A common feature of these diseases is vascular smooth muscle cell (VSMC) dysfunction on small arterial blood vessels leading to episodes of impaired blood perfusion in certain brain regions.</p><p id="Par3">Since VSMC are critical regulators to maintain vascular homeostasis they show high phenotypic plasticity, where contractile and synthetic VSMC represent the two ends of a spectrum with intermediate phenotypes, which have different morphologies and functions. While na&#x000ef;ve VSMC display a synthetic phenotype and are unable to contract but important for maintenance, contractile VSMC control blood flow and pressure. During development, vascular remodeling and injury, synthetic VSMC secrete extracellular matrix proteins and exhibit higher growth rates and migratory activity than contractile VSMC<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par4">Notch signaling is a juxtacrine signaling mode, which controls numerous cell differentiation processes. The signal sending cell expresses Notch ligands of the Delta-like (DLL) and Jagged (JAG) families which activate Notch receptors on adjacent signal receiving cells. The interaction induces receptor cleavage and translocation of the Notch intracellular domain (ICD) to the nucleus, where it interacts with RBP-J&#x003ba; and promotes cell type-specific gene expression and induction of the <italic>HES</italic> and <italic>HEY</italic> genes. These encode basic helix-loop-helix (bHLH) transcription factors, which repress gene expression through either binding other bHLH factors or through interacting directly with DNA at promoter regions<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. In muscle stem cells, HeyL interacts with Hes1 to bind DNA sites with high affinity causing anti-myogenic effects<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. In VSMC, HES and HEY proteins can inhibit transcription of contractile VSMC marker proteins<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. As such, the effect of Notch signaling on promoting the contractile VSMC phenotype can be counteracted by HES and HEY bHLH factors. This indicates that the outcome of Notch signaling activity is strictly dose-dependent.</p><p id="Par5">Similar to the Notch pathway, TGF&#x003b2; signaling has also been shown to promote VSCM differentiation<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Interestingly, TGF&#x003b2; signaling can also activate <italic>HEY</italic> and <italic>HES</italic> gene expression in certain cell types<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Provided that this also occurs in VSMC, HTRA1 might function through controlling expression levels of the <italic>HES</italic> and <italic>HEY</italic> transcriptional repressors via Notch and TGF&#x003b2; signaling.</p><p id="Par6">Here we aimed at better understanding how the serine protease HTRA1 controls Notch and TGF&#x003b2; signaling in VSMC and how this affects the VSCM phenotype. HTRA1 is strongly expressed in VSMC and endothelial cells<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup> and is known to cleave several intracellular<sup><xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref></sup> and extracellular substrates<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. Loss of <italic>HTRA1</italic> leads to increased levels of TGF&#x003b2;1 availability and TGF&#x003b2;1 signaling, potentially caused by the ability of HTRA1 to cleave either pro-TGF&#x003b2;1 or GFD6<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref></sup>. Recently, we have shown that the Notch ligand JAG1 is a substrate for HTRA1. After cleavage of JAG1 by HTRA1 in the cytosol the remaining JAG1 protein was rapidly degraded<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. NOTCH3 and JAG1 are both abundantly expressed on VSMC<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. In arterial blood vessels, JAG1/NOTCH3 signaling is required for differentiation, maintenance and contractility of VSMC<sup><xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref></sup>, which is crucial for vasoconstriction and proper organ perfusion. Such blood vessel functions are impaired in familial small vessel disease. Thus, we hypothesized that HTRA1 functions not only to control TGF&#x003b2; signaling but also to fine-tune NOTCH3 activity in VSMC by regulating the abundance of its ligand JAG1. As both signaling pathways are critically involved in controlling VSMC differentiation<sup><xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>, loss of <italic>HTRA1</italic> may lead to impaired VSMC function and vessel contraction capacity.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Loss of <italic>HTRA1</italic> in VSMC increases NOTCH3 signaling</title><p id="Par7">The similarities between CARASIL and CADASIL syndromes<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>, as well as our recent finding that HTRA1 cleaves the Notch ligand JAG1<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, prompted us to investigate the potential interplay between HTRA1 and NOTCH3 signaling. Therefore, <italic>HTRA1</italic> was silenced in primary human umbilical artery SMC (HUASMC) using established siRNAs<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref><bold>)</bold>. We observed that silencing <italic>HTRA1</italic> increased mRNA levels of the Notch target genes <italic>HES1</italic> and <italic>HEYL</italic> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). Higher Notch signaling activity was further evidenced by increased NOTCH3-ICD protein levels and increased JAG1 protein levels (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>Increased Notch3 signaling activity in <italic>Htra1-</italic>silenced VSMC. (<bold>a</bold>) <italic>HTRA1</italic> was silenced with siRNA. Representative Western blot of HUASMC protein lysates probed with HTRA1 antibody. (<bold>b</bold>) Quantitative real-time PCR analysis of Notch target gene transcripts in HUASMC after silencing <italic>HTRA1</italic> (n&#x02009;=&#x02009;3). (<bold>c</bold>) Representative Western blot of HUASMC protein lysates probed with anti-JAG1 and anti-NOTCH3-ICD and quantification of band intensities (n&#x02009;=&#x02009;3). (<bold>d</bold>) Immunoblot of protein lysates derived from mesenteric arteries of <italic>HtrA1</italic><sup>+/+</sup> and <italic>HtrA1</italic><sup>&#x02212;/&#x02212;</sup> mice probed with anti-Notch3-ICD and anti-JAG1 antibody and quantification of band intensities (n&#x02009;=&#x02009;3). (<bold>e</bold>) Quantitative real-time PCR analysis of Notch target gene transcripts in mesenteric arteries derived from <italic>HtrA1</italic><sup>+/+</sup> and <italic>HtrA1</italic><sup>&#x02212;/&#x02212;</sup> mice (n&#x02009;=&#x02009;3). Statistical significance was determined by an unpaired student&#x02019;s t-test (<bold>b</bold>&#x02013;<bold>e</bold>). *p&#x02009;&#x0003c;&#x02009;0.05. Bar graphs show mean values, error bars indicate SD.</p></caption><graphic xlink:href="41598_2019_54807_Fig1_HTML" id="d29e626"/></fig></p><p id="Par8">We next isolated arteries from adult <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice to verify these data in an <italic>in vivo</italic> model. Compared to wild-type littermate controls, there was an increase in NOTCH3-ICD and JAG1 protein levels in isolated mesenteric resistance arteries from <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>), indicating augmented NOTCH3 signaling activity. Consistently, we observed a substantial increase in <italic>Hes1</italic> and <italic>HeyL</italic> mRNA levels in mesenteric arteries isolated from <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1e</xref>).</p></sec><sec id="Sec4"><title>Loss of <italic>HTRA1</italic> in VSMC increases TGF&#x003b2; signaling</title><p id="Par9">Several reports have shown increased TGF&#x003b2;1 availability and TGF&#x003b2; signaling upon loss of <italic>HTRA1</italic><sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. In HUASMC, silencing of <italic>HTRA1</italic> led to an induction of TGF&#x003b2; signaling activity as evidenced by elevated levels of phosphorylated SMAD2/3 proteins (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a,b</xref>). In addition, Smad2/3 phosphorylation levels were higher in isolated arteries from <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice when compared to wild-type littermate controls (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c,d</xref>). Furthermore, when co-cultured with 3T3 reporter cells, silencing of <italic>HTRA1</italic> in HUASMC increased SMAD-dependent luciferase activity (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>), indicating that loss of <italic>Htra1</italic> in VSMC results in increased TGF&#x003b2; signaling in adjacent cells.<fig id="Fig2"><label>Figure 2</label><caption><p>Loss of <italic>HTRA1</italic> in VSMC enforces TGF&#x003b2; signaling and induces dual induction of <italic>HES</italic> and <italic>HEY</italic> transcriptional repressors synergistically with NOTCH3. (<bold>a</bold>) Immunoblot of phosphorylated SMAD2/3 protein expression after siRNA-mediated silencing of <italic>HTRA</italic>1 in HUASMC. (<bold>b</bold>) Graphical representation of fold change in phosphorylated SMAD2/3 protein level (n&#x02009;=&#x02009;3). (<bold>c</bold>) Immunoblot of pSMAD2/3 protein level in mesenteric arteries obtained from <italic>HtrA1</italic><sup>+/+</sup> and <italic>HtrA1</italic><sup>&#x02212;/&#x02212;</sup> mice. (<bold>d</bold>) Graphical representation of fold change in pSMAD2/3 protein level (n&#x02009;=&#x02009;3). (<bold>e</bold>) Co-culture experiment with HUASMC and 3T3 TGF&#x000df; reporter cells expressing a luciferase cassette with a SMAD responsive promotor (n&#x02009;=&#x02009;3). (<bold>f</bold>) Western blot of HUASMC protein lysates probed with anti-pSMAD2/3 antibody after stimulation with TGF&#x000df;1 (5&#x02009;ng/ml). (<bold>g</bold>) Quantitative real-time PCR analysis of Notch target gene transcripts in HUASMC after TGF&#x000df;1 stimulation, NOTCH3 stimulation via immobilized JAG1 ligands or combination of TGF&#x000df;1 and NOTCH3 stimulation (n&#x02009;=&#x02009;3). (<bold>h</bold>) Quantitative real-time PCR analysis of Notch target gene transcripts in control and <italic>HTRA1</italic>-silenced HUASMC after two hours of TGF&#x000df; inhibition using 10&#x02009;&#x000b5;M ALK5 inhibitor (ALK5i, CAS 446859-33-2, Merck) or NOTCH3 inhibition for 16&#x02009;hours using 25&#x02009;&#x000b5;M DAPT (Merck). The dashed line denotes gene expression level of control cells (sh-ctrl) treated with DMSO (n&#x02009;=&#x02009;3). Statistical significance was determined by an unpaired student&#x02019;s t-test (<bold>b</bold>,<bold>d</bold>,<bold>e</bold>) or by 1-way ANOVA followed by Dunnett post-hoc test (<bold>g</bold>,<bold>h</bold>). *p&#x02009;&#x0003c;&#x02009;0.05; **p&#x02009;&#x0003c;&#x02009;0.01; ***p&#x02009;&#x0003c;&#x02009;0.001. Bar graphs show mean values, error bars indicate SD.</p></caption><graphic xlink:href="41598_2019_54807_Fig2_HTML" id="d29e782"/></fig></p></sec><sec id="Sec5"><title>NOTCH3 and TGF&#x003b2; signaling induces <italic>HES</italic> and <italic>HEY</italic> expression</title><p id="Par10">We and others have shown that TGF&#x003b2;1 and BMPs can activate <italic>HEY</italic> and <italic>HES</italic> gene expression via SMAD proteins in endothelial cells<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. To examine whether this also applies to VSMC, we treated HUASMC with recombinant TGF&#x003b2;1 and observed not only increased phosphorylation of SMAD2/3 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref>), but also increased transcription of <italic>HES1</italic> and <italic>HEYL</italic> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2g</xref>). To test this further, we stimulated NOTCH3 signaling in HUASMC using immobilized JAG1 ligands. While stimulation with JAG1 did not significantly affect <italic>HEY</italic> and <italic>HES</italic> gene transcription, combined treatment with JAG1 and TGF&#x003b2;1 led to an additive induction of <italic>HES1</italic>, <italic>HES5</italic> and <italic>HEYL</italic> expression (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2g</xref>). Of note, the induction of <italic>HES</italic> and <italic>HEY</italic> genes upon silencing of <italic>HTRA1</italic> was fully reverted by inhibiting Notch signaling with the gamma-secretase inhibitor DAPT as well as by inhibiting TGF&#x003b2; signaling using the ALK5 inhibitor CAS 446859-33-2 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2h</xref>).</p><p id="Par11">Taken together, these experiments revealed that loss of <italic>HTRA1</italic> leads to over-activation of NOTCH3 and TGF&#x003b2; signaling, two pathways that synergistically stimulate expression of <italic>HES</italic> and <italic>HEY</italic> transcriptional repressors.</p></sec><sec id="Sec6"><title>Loss of <italic>HTRA1</italic> leads to decreased contractile protein expression</title><p id="Par12">Notch signaling is essential for the differentiation of VSMC from precursor cells and for maintenance of the contractile phenotype. JAG1 and NOTCH3 are the most abundantly expressed ligands and receptors respectively on VSMC. Several studies have shown that NOTCH3-ICD activates the transcription of contractile proteins, whereas Notch target genes of <italic>HES</italic> and <italic>HEY</italic> families, encoding transcriptional repressor proteins, inhibit the expression of these contractile VSMC markers<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par13">Therefore, we analyzed the effect of HTRA1 on expression of contractile proteins. Western blotting revealed a strong reduction of the contractile VSMC phenotype marker proteins &#x003b1;-SMA and SM22&#x003b1; upon silencing of <italic>HTRA1</italic> in HUASMC (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). Similar to cultured VSMC, the protein expression levels of SM22&#x003b1; and &#x003b1;-SMA were diminished in the arterial wall of <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice compared to wild-type littermate controls (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b,c</xref>). Furthermore, the mRNA expression levels of classical contractile VSMC phenotype marker genes <italic>SM22&#x003b1;</italic>, <italic>&#x003b1;-SMA</italic> and <italic>Smoothelin</italic> were diminished after silencing <italic>HTRA1</italic> in HUASCM (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p><italic>Htra1</italic> silencing inhibits contractile protein expression. (<bold>a</bold>) Immunoblot and quantification of contractile proteins in control or <italic>HTRA1</italic>-silenced HUASMC (n&#x02009;=&#x02009;3). (<bold>b</bold>) Immunoblot and graphical representation of fold change in SM22&#x003b1; protein expression in mesenteric arteries (n&#x02009;=&#x02009;3). (<bold>c</bold>) Immunoblot and graphical representation of fold change in &#x003b1;-SMA protein expression in mesenteric arteries (n&#x02009;=&#x02009;3). (<bold>d</bold>) Quantitative real-time PCR analysis of contractile gene transcripts in <italic>HTRA1</italic>-silenced HUASMC (n&#x02009;=&#x02009;3). (<bold>e</bold>) Representative immunoblot of HUASMC protein lysates probed with anti-NOTCH3-ICD and anti-SM22&#x003b1; antibodies. (<bold>f</bold>) Quantitative real-time PCR analysis of contractile gene transcripts in HUASMC overexpressing <italic>HEYL</italic> and <italic>HES1</italic> (n&#x02009;=&#x02009;3). Statistical significance was determined by an unpaired student&#x02019;s t-test (<bold>a</bold>,<bold>b</bold>,<bold>c</bold>,<bold>d</bold>,<bold>f</bold>). *p&#x02009;&#x0003c;&#x02009;0.05; **p&#x02009;&#x0003c;&#x02009;0.01. Bar graphs show mean values, error bars indicate SD.</p></caption><graphic xlink:href="41598_2019_54807_Fig3_HTML" id="d29e972"/></fig></p><p id="Par14">To further analyze how hyperactive NOTCH3 signaling contributed to the observed changes seen after <italic>HTRA1</italic> knockdown, we expressed increasing amounts of NOTCH3-ICD in HUASMC. As expected based on previous reports<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>, moderate over-expression of NOTCH3-ICD led to substantially increased SM22&#x003b1; protein levels (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3e</xref>). This result was however contradictory to what we observed after <italic>HTRA1</italic> silencing (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a&#x02013;d</xref>) questioning the relevance of Notch signaling downstream of HTRA1. Interestingly, with higher NOTCH3-ICD expression levels the expression of SM22&#x003b1; decreased again (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3e</xref>), indicating hyper-activation of a negative feedback loop. Indeed, combined over-expression of HES1 and HEYL repressed transcription of <italic>&#x003b1;-SMA</italic> and <italic>SM22&#x003b1;</italic> in HUASMC (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref>).</p><p id="Par15">Taken together, these data suggest that the strong upregulation of HES and HEY transcriptional repressors by increased Notch and TGF&#x003b2; signaling upon loss of <italic>HTRA1</italic> leads to repression of genes encoding contractile proteins in VSMC.</p></sec><sec id="Sec7"><title>Loss of <italic>HTRA1</italic> in VSMC impairs contractility</title><p id="Par16">Impaired vascular contractility contributes to the development of small vessel disease<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Therefore, we investigated whether loss of <italic>HTRA1</italic> affects VSMC differentiation and function. Immunofluorescence microscopy revealed substantially less actin and myosin fibers in cultured VSMC after <italic>HTRA1</italic> knockdown (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). The impairment of F-actin formation upon <italic>HTRA1</italic> silencing was restored by inhibition of Notch signaling using DAPT or by inhibition of TGF&#x003b2; signaling using the ALK5 inhibitor CAS 446859-33-2 (ALK5i) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>).<fig id="Fig4"><label>Figure 4</label><caption><p>Contractile gene expression in <italic>HTRA1</italic>-deficient VSMC is affected by Notch and TGF&#x000df; signaling. (<bold>a</bold>) Representative photomicrographs of F-actin and immunolabeled myosin in HUASMC and quantification of F-actin and myosin positive areas (n&#x02009;=&#x02009;4). (<bold>b</bold>) Representative photomicrographs of F-actin in HUASMC after four hours of TGF&#x000df; inhibition using 10&#x02009;&#x000b5;M ALK5 inhibitor (ALK5i, CAS 446859-33-2, Merck) or NOTCH3 inhibition for 16&#x02009;hours using 25&#x02009;&#x000b5;M DAPT (Merck) (n&#x02009;=&#x02009;3). (<bold>c</bold>&#x02013;<bold>e</bold>) Primary aortic VSMC derived from HtrA1<sup>&#x02212;/&#x02212;</sup> or wildtype littermate controls were cultured until confluence was reached. Quantitative real-time PCR analysis of alpha smooth muscle actin (&#x003b1;-SMA). (<bold>d</bold>,<bold>e</bold>) VSMC were treated with DAPT (25&#x02009;&#x000b5;M) for 16&#x02009;hours or Alk5i (10&#x02009;&#x000b5;M) for two hours before RNA isolation. Treatment with the solvent DMSO was used as control (n&#x02009;=&#x02009;3). Statistical significance was determined by an unpaired student&#x02019;s t-test (<bold>a,c,d,e</bold>). *p&#x02009;&#x0003c;&#x02009;0.05; **p&#x02009;&#x0003c;&#x02009;0.01. Bar graphs show mean values, error bars indicate SD. Scale bar equals 10&#x02009;&#x000b5;m.</p></caption><graphic xlink:href="41598_2019_54807_Fig4_HTML" id="d29e1088"/></fig></p><p id="Par17">Next primary aortic VSMC were isolated from HtrA1<sup>&#x02212;/&#x02212;</sup> mice. As expected these had lower <italic>&#x003b1;-SMA</italic> mRNA expression levels compared to aortic VSMC isolated from their wildtype littermate controls (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>). While inhibiting Notch activity with DAPT or TGF&#x003b2; signaling using ALK5i lowered <italic>&#x003b1;-SMA</italic> mRNA expression in wildtype VSMC (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d</xref>), they partially restored <italic>&#x003b1;-SMA</italic> expression in HtrA1<sup>&#x02212;/&#x02212;</sup> aortic VSMC (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e</xref>).</p><p id="Par18">To further analyze whether <italic>HTRA1</italic> silencing deteriorates cell contractility, we measured the extent of collagen gel contraction by HUASMC. Indeed, cells silenced for <italic>HTRA1</italic> expression were severely impaired in their ability to contract collagen gels when compared to control cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>).<fig id="Fig5"><label>Figure 5</label><caption><p>Loss of <italic>HTRA1</italic> in VSMC impairs contractility. (<bold>a</bold>) Cell contraction of control and <italic>HTRA1</italic>-silenced HUASMC at indicated time-points (n&#x02009;=&#x02009;3). (<bold>b</bold>) Relative increase in diameter of mesenteric artery segments from <italic>HtrA1</italic><sup>+/+</sup> and <italic>HtrA1</italic><sup>&#x02212;/&#x02212;</sup> mice challenged with increasing intraluminal pressure. Diameter of unchallenged arteries was set to 100%. Statistical significance was determined by an unpaired student&#x02019;s t-test (<bold>a</bold>,<bold>b</bold>). *p&#x02009;&#x0003c;&#x02009;0.05; **p&#x02009;&#x0003c;&#x02009;0.01; ***p&#x02009;&#x0003c;&#x02009;0.001. Bar graphs show mean values, error bars indicate SD.</p></caption><graphic xlink:href="41598_2019_54807_Fig5_HTML" id="d29e1164"/></fig></p><p id="Par19">SM22&#x003b1; is needed to bundle actin filaments that interact with myosin fibers<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Although <italic>SM22&#x003b1;</italic><sup>&#x02212;/&#x02212;</sup> mice are viable, they show impaired vasoconstriction<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. Based on this, we tested how 3<sup>rd</sup> order branches of mesenteric resistance arteries isolated from <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice respond to an increase in blood pressure. Consistent with the <italic>in vitro</italic> data, we observed a less pronounced pressure response in mesenteric arteries from <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice compared to control mice, suggesting a switch from contractile to synthetic phenotype (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). We therefore conclude that HTRA1 is required for VSMC maturation and for appropriate contraction of small resistance arteries.</p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p id="Par20"><italic>HTRA1</italic> mutations or altered expression levels of this gene are associated with several diseases, whose pathogenesis is mainly driven by impaired blood vessel function. In humans, <italic>NOTCH3</italic> and <italic>HTRA1</italic> are two of the most frequently mutated genes in familial small vessel disease which is a major cause of stroke and vascular dementia<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Moreover, disturbed VSMC function and integrity are main pathogenic factors in small vessel diseases, which impair white matter perfusion leading to dementia<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. For example, attenuated myogenic responses, reduced caliber of brain arteries and impaired cerebrovascular autoregulation were detected in a mouse model of CADASIL<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. In autopsies of CARASIL patients, degeneration and loss of VSMC and extracellular matrix proteins, and in addition also severe adventitial fibrosis in small and medium-sized arteries were observed<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par21">Our study shows that the serine protease HTRA1 controls not only TGF&#x003b2; signaling but also Notch3 signaling, a central regulator of VSMC function. The data suggest that HTRA1 is needed for full VSMC differentiation into the contractile phenotype. In agreement with this, it was very recently reported that VSMC in aged <italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice adopt the synthetic phenotype and are prone to cell death<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Similar to loss of <italic>NOTCH3</italic><sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> or overexpression of CADASIL-related <italic>NOTCH3</italic> mutations<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, loss of <italic>HTRA1</italic> is compatible with normal development of the knockout mouse<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. However, our data demonstrate that under stressful situations, reduced expression levels of contractile proteins may impair proper blood perfusion.</p><p id="Par22">Furthermore, the data indicate that HTRA1 is required to limit the activity of NOTCH3 and TGF&#x003b2; signaling in VSMC. TGF&#x003b2; and NOTCH3 signaling induce VSMC differentiation<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> and synergistically activate expression of contractile marker proteins<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> whereupon the Notch transducer RBP-J&#x003ba; interacts with Smad2/3 and increases its transcriptional activity. Many promoters of VSMC marker genes contain RBP-J&#x003ba; and Smad consensus binding sites in close proximity, suggesting combined action as a transcriptional activator complex<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Our data highlight that the outcome of NOTCH3 and TGF&#x003b2; signaling in VSMC is highly dependent on the signaling strength. While both pathways activate the expression of contractile genes, they also activate <italic>HES</italic> and <italic>HEY</italic> transcriptional repressors. These counteract the Notch-induced up-regulation of contractile proteins like smooth muscle actin<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. We therefore conclude that the combined over-activation of Notch and TGF&#x003b2; signaling in <italic>Htra1</italic>-deficient VSMC may counteract the expression of contractile proteins by inappropriately high <italic>HES</italic> and <italic>HEY</italic> gene expression.</p><p id="Par23">In summary, we demonstrated the first functional link between HTRA1 and NOTCH3 signaling. The similar clinical presentation of CARASIL and CADASIL syndromes<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> and a recent report about aberrant HTRA1 protein levels in a CADASIL mouse model<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> already suggested such a potential connection. Future work will address how aberrant JAG1 expression influences VSMC biology and how this may be involved in the pathogenesis of small vessel diseases.</p></sec><sec id="Sec9" sec-type="materials|methods"><title>Material and Methods</title><sec id="Sec10"><title>Animals and procedures</title><p id="Par24"><italic>Htra1</italic><sup>&#x02212;/&#x02212;</sup> mice on a C57/Bl6 background were described before<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Mice were kept under pathogen-free barrier conditions and animal procedures were performed in accordance with the institutional and national regulation. The local authorities approved all animal experiments.</p></sec><sec id="Sec11"><title>Perfusion of isolated mouse arteries</title><p id="Par25">Mice were sacrificed and second/third order mesenteric arteries were isolated and perfused with Tyrode buffer at a longitudinal pressure gradient of 20&#x02009;mm Hg (70&#x02013;110&#x02009;mmHg at the inflow and 50&#x02013;90&#x02009;mmHg at the outflow) with a resulting flow of ~0.07&#x02009;mL/min. Arteries which showed no myogenic response were excluded from the analyses. Pressure-induced changes in vessel diameter were measured using the VediView software (DMT, Copenhagen, Denmark).</p></sec><sec id="Sec12"><title>Human vascular smooth muscle cell isolation and cultivation</title><p id="Par26">VSMC were freshly isolated and cultured as previously described<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Transfection of cells was done as previously described<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Generation of lentivirus and transduction of cells with lentivirus was done as shown elsewhere<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. To inhibit Notch signaling, cells were incubated with 25&#x02009;&#x000b5;M DAPT (Merck) overnight. TGF&#x003b2; signaling was inhibited by adding 10&#x02009;&#x000b5;M ALK5 inhibitor (CAS 446859-33-2, Merck) for two hours to basal cell medium.</p><p id="Par27">For the co-culture experiment, the same numbers of HUASMC were seeded with 3T3 cells expressing a TGF&#x003b2; reporter (Luciferase cassette under the control of 12 SMAD binding sites (5&#x02032;-CAGA-3&#x02032;) and cultured overnight in basal medium. Luciferase activity was determined using the Luciferase Assay System (E1500, Promega) and a multiwell plate reader (Clariostar, BMG Labtech).</p><p id="Par28">Adenovirus was obtained from abm Inc. (Vancouver, Canada): HES1 (096900&#x02009;A), HEYL (096954&#x02009;A). HUASMC were infected with MOI&#x02009;=&#x02009;50 and cell lysate were prepared 24&#x02009;hours later.</p></sec><sec id="Sec13"><title>Mouse aortic VSMC isolation</title><p id="Par29">Mice were sacrificed by cervical dislocation. After exposing the heart and the descending aorta, fat and adventitia were dissected. The aorta was removed and rinsed in a 60&#x02009;mm dish with cold PBS containing penicilin and streptomycin and cut into small rings, approximately 1&#x02009;mm long. Rings were transferred in new 35&#x02009;mm dishes with 2&#x02009;ml DMEM with 15% FBS and penicilin/streptomycin containing collagenase at a 10&#x02009;mg/ml concentration. Rings were incubated overnight. On the next day aortic rings and cells in suspension were transferred to a 15&#x02009;ml tube, centrifuged (1000&#x02009;rpm, 5&#x02009;minutes) and suspended in DMEM with 15% FBS. Cells were incubated until confluence was reached.</p></sec><sec id="Sec14"><title>RNA extraction and real-time PCR analysis</title><p id="Par30">Total RNA was isolated using the innuPREP RNA Mini Kit (Analytik Jena). cDNA was synthesized from 1&#x02009;&#x000b5;g of DNA-free total RNA using M-MLV Reverse Transcriptase (Life Technologies) and random hexamer primers (Life Technologies). Gene-specific transcription levels were determined using the POWER SYBR-Green Mastermix (Life Technologies) and an ABI StepOnePlus real-time cycler (Applied Biosystems). Ct-values were determined with LinReg software and normalization was done with the housekeeping genes OAZ1 (human) and Gapdh (mouse). Primers used were as follows: hOAZ (fw): 5&#x02032;-gagccgaccatgtcttcatt-3&#x02032;, hOAZ (rev): 5&#x02032;-ctcctcctctcccgaagact-3&#x02032;; mGapdh (fw): 5&#x02032;-aactttggcattgtggaagg-3&#x02032;, mGapdh (rev): 5&#x02032;-acacattgggggtaggaaca-3&#x02032;; hHES1 (fw): 5&#x02032;-tcaacacgacaccggataaa-3&#x02032;, hHES1 (rev): 5&#x02032;-ccgcgagctatctttcttca-3&#x02032;; mHes1 (fw): 5&#x02032;-gtcacctcgttcatgcactc-3&#x02032;, mHes1 (rev): 5&#x02032;-tctggaaatgactgtgaagca-3&#x02032;; hHES5 (fw): 5&#x02032;-gcatggcccccagca-3&#x02032;, hHES5 (rev): 5&#x02032;-acgaaggctttgctgtgctt-3&#x02032;; mHes5 (fw): 5&#x02032;-caaggagaaaaaccgactgc-3&#x02032;, mHes5 (rev): 5&#x02032;-ggctttgctgtgtttcaggt-3&#x02032;; hHEYL (fw): 5&#x02032;-gcaagccaggaagaaacaca-3&#x02032;, hHEYL (rev): 5&#x02032;-agaatcctgtcccaccagtg-3&#x02032;; mHeyL (fw): 5&#x02032;-tatgatccctctgcgcttct-3&#x02032;, mHeyL (rev): 5&#x02032;-catcgatgtgggtcaagaga-3&#x02032;; h&#x003b1;-SMA (fw): 5&#x02032;-ctgttccagccatccttcat-3&#x02032;, h&#x003b1;-SMA (rev): 5&#x02032;-ccgtgatctccttctgcatt-3&#x02032;; hSMTN (fw): 5&#x02032;-cctggtgcacaacttcttcc-3&#x02032;, hSMTN (rev): 5&#x02032;-aagacacacttggggtcagg-3&#x02032;; hCNN1 (fw): 5&#x02032;-ggagctgagagagtggatcg-3&#x02032;, hCNN1 (rev): 5&#x02032;-gtgccaattttgggttgact-3&#x02032;; hMYH11 (fw): 5&#x02032;-gtgaacgcactcaagagcaa-3&#x02032;, hMYH11 (rev): 5&#x02032;-tattcactggccttggttcc-3&#x02032;</p></sec><sec id="Sec15"><title>Western Blot analysis</title><p id="Par31">Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Whatman). The membranes were blocked with 5% skim milk or 3% bovine serum albumin in 0.1% Tween-20 in TBS and incubated with primary antibodies at 4&#x02009;&#x000b0;C over-night. The membranes were incubated with peroxidase-conjugated secondary antibody for 2&#x02009;hours at room temperature followed by ECL detection of the antibody. Band intensities were analyzed by the Image lab software (Biorad).</p></sec><sec id="Sec16"><title>Antibodies</title><p id="Par32">Anti-JAG1 (Santa Cruz, sc-6011), anti-HTRA1 (R&#x00026;D, MAB2916), anti-GAPDH (abcam, ab8245), anti-&#x003b1;-SMA (Sigma, C6198), anti-SM22&#x003b1; (abcam, ab137453), anti-NOTCH3 (Santa Cruz, sc-5593), anti-myosin (eBioscience, 14-6400), pSMAD2/3 (Cell Signaling, #8828) were used as primary antibodies. F-actin was stained with Alexa Fluor 568-conjugated phalloidin (Invitrogen).</p></sec><sec id="Sec17"><title>Immunofluorescence staining</title><p id="Par33">HUASMC were seeded on glass slides coated with 0.5% gelantine. Cells were washed twice with PBS, fixed with 4% PFA for 10&#x02009;min, washed three times with PBS, permeabilized with PBS-T (containing 0.1% TritonX) and washed again three times with PBS. After blocking with 3% BSA in PBS, cells were incubated with the primary antibodies over night at 4&#x02009;&#x000b0;C and secondary antibodies (Thermo Fisher Scientific, 1:400) for 1&#x02009;hour at room temperature. Sections were counterstained with DAPI, washed three times with PBS and mounted with Fluoromount (S3023, Dako). Confocal images were obtained using an LSM 700 microscope (Carl Zeiss) and analyzed using Fiji software.</p></sec><sec id="Sec18"><title>Statistical analysis</title><p id="Par34">Statistical analysis was performed with the Prism 6.0 software (GraphPad Software). Statistical significance was determined by an unpaired student t-test for two samples or by 1-way ANOVA followed by Dunnett post-hoc test when more than 2 groups were compared. Statistical significance is indicated as *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001.</p></sec><sec id="Sec19"><title>Study approval</title><p id="Par35">Human umbilical smooth muscle cells were freshly isolated from umbilical cords according to the declaration of Helsinki and with approval of the Heidelberg University ethics review board. Written informed consent from the donor was obtained prior to inclusion in the study. The Animal Care and Use Committee of the Bezirksregierung Baden-W&#x000fc;rttemberg, Germany, approved all procedures performed on mice.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec20"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2019_54807_MOESM1_ESM.pdf"><caption><p>Supplementary figure</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>is available for this paper at 10.1038/s41598-019-54807-6.</p></sec><ack><title>Acknowledgements</title><p>We thank the members of the DKFZ laboratory animal facility for excellent support. This work was supported by the Fritz-Thyssen Foundation (10.13.1.160 to A.F.) and the Deutsche Forschungsgemeinschaft (DFG) - project number 394046768 - SFB1366 (to A.F. and T.K.).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>R.K., A.P., F.T., E.M.W., I.M., T.K., J.R.V. and A.F. conceived and designed experiments and analyzed the data; C.O. provided essential reagents and discussed data; R.K., F.T., E.M.W. and A.F. wrote the manuscript.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par36">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdura</surname><given-names>E</given-names></name><etal/></person-group><article-title>Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>2347</fpage><lpage>2358</lpage><pub-id pub-id-type="doi">10.1093/brain/awv155</pub-id><pub-id pub-id-type="pmid">26063658</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>1729</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0801560</pub-id><pub-id pub-id-type="pmid">19387015</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikka</surname><given-names>S</given-names></name><etal/></person-group><article-title>CADASIL and CARASIL</article-title><source>Brain Pathol</source><year>2014</year><volume>24</volume><fpage>525</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1111/bpa.12181</pub-id><pub-id pub-id-type="pmid">25323668</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>GK</given-names></name></person-group><article-title>Regulation of differentiation of vascular smooth muscle cells</article-title><source>Physiol Rev</source><year>1995</year><volume>75</volume><fpage>487</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1152/physrev.1995.75.3.487</pub-id><pub-id pub-id-type="pmid">7624392</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Gessler</surname><given-names>M</given-names></name></person-group><article-title>Delta-Notch&#x02013;and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors</article-title><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><fpage>4583</fpage><lpage>4596</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm477</pub-id><pub-id pub-id-type="pmid">17586813</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Noguchi, Y. T. <italic>et al</italic>. Cell-autonomous and redundant roles of Hey1 and HeyL in muscle stem cells: HeyL requires Hes1 to bind diverse DNA sites. <italic>Development</italic><bold>146</bold>, 10.1242/dev.163618 (2019).</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boucher</surname><given-names>J</given-names></name><name><surname>Gridley</surname><given-names>T</given-names></name><name><surname>Liaw</surname><given-names>L</given-names></name></person-group><article-title>Molecular pathways of notch signaling in vascular smooth muscle cells</article-title><source>Front Physiol</source><year>2012</year><volume>3</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.3389/fphys.2012.00081</pub-id><pub-id pub-id-type="pmid">22509166</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouillade</surname><given-names>C</given-names></name><name><surname>Monet-Lepretre</surname><given-names>M</given-names></name><name><surname>Baron-Menguy</surname><given-names>C</given-names></name><name><surname>Joutel</surname><given-names>A</given-names></name></person-group><article-title>Notch signalling in smooth muscle cells during development and disease</article-title><source>Cardiovasc Res</source><year>2012</year><volume>95</volume><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvs019</pub-id><pub-id pub-id-type="pmid">22266753</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name></person-group><article-title>Transforming growth factor-beta and smooth muscle differentiation</article-title><source>World J Biol Chem</source><year>2012</year><volume>3</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.4331/wjbc.v3.i3.41</pub-id><pub-id pub-id-type="pmid">22451850</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>F</given-names></name><etal/></person-group><article-title>Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600065</pub-id><pub-id pub-id-type="pmid">14739937</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woltje</surname><given-names>K</given-names></name><name><surname>Jabs</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name></person-group><article-title>Serum induces transcription of Hey1 and Hey2 genes by Alk1 but not Notch signaling in endothelial cells</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0120547</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0120547</pub-id><pub-id pub-id-type="pmid">25799559</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>A</given-names></name><etal/></person-group><article-title>Distribution of the serine protease HtrA1 in normal human tissues</article-title><source>J Histochem Cytochem</source><year>2003</year><volume>51</volume><fpage>1279</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1177/002215540305101004</pub-id><pub-id pub-id-type="pmid">14500695</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oka</surname><given-names>C</given-names></name><etal/></person-group><article-title>HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins</article-title><source>Development</source><year>2004</year><volume>131</volume><fpage>1041</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1242/dev.00999</pub-id><pub-id pub-id-type="pmid">14973287</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campioni</surname><given-names>M</given-names></name><etal/></person-group><article-title>The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein</article-title><source>Mol Cancer Res</source><year>2010</year><volume>8</volume><fpage>1248</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-09-0473</pub-id><pub-id pub-id-type="pmid">20671064</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>J</given-names></name><etal/></person-group><article-title>Serine protease HtrA1 associates with microtubules and inhibits cell migration</article-title><source>Mol Cell Biol</source><year>2009</year><volume>29</volume><fpage>4177</fpage><lpage>4187</lpage><pub-id pub-id-type="doi">10.1128/MCB.00035-09</pub-id><pub-id pub-id-type="pmid">19470753</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grau</surname><given-names>S</given-names></name><etal/></person-group><article-title>Implications of the serine protease HtrA1 in amyloid precursor protein processing</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>6021</fpage><lpage>6026</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501823102</pub-id><pub-id pub-id-type="pmid">15855271</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tennstaedt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>20931</fpage><lpage>20941</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.316232</pub-id><pub-id pub-id-type="pmid">22535953</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiaden</surname><given-names>AN</given-names></name><name><surname>Richards</surname><given-names>PJ</given-names></name></person-group><article-title>The emerging roles of HTRA1 in musculoskeletal disease</article-title><source>Am J Pathol</source><year>2013</year><volume>182</volume><fpage>1482</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.02.003</pub-id><pub-id pub-id-type="pmid">23499460</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>U</given-names></name><etal/></person-group><article-title>Synonymous variants in HTRA1 implicated in AMD susceptibility impair its capacity to regulate TGF-beta signaling</article-title><source>Hum Mol Genet</source><year>2015</year><volume>24</volume><fpage>6361</fpage><lpage>6373</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv346</pub-id><pub-id pub-id-type="pmid">26310622</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiga</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cerebral small-vessel disease protein HTRA1 controls the amount of TGF-beta1 via cleavage of proTGF-beta1</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><fpage>1800</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr063</pub-id><pub-id pub-id-type="pmid">21320870</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>High temperature requirement factor A1 (HTRA1) gene regulates angiogenesis through transforming growth factor-beta family member growth differentiation factor 6</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>1520</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.275990</pub-id><pub-id pub-id-type="pmid">22049084</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Klose, R. <italic>et al</italic>. Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis. <italic>Oncogene</italic>, 10.1038/s41388-018-0258-4 (2018).</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulos</surname><given-names>N</given-names></name><etal/></person-group><article-title>Notch3 is essential for regulation of the renal vascular tone</article-title><source>Hypertension</source><year>2011</year><volume>57</volume><fpage>1176</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.111.170746</pub-id><pub-id pub-id-type="pmid">21518968</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domenga</surname><given-names>V</given-names></name><etal/></person-group><article-title>Notch3 is required for arterial identity and maturation of vascular smooth muscle cells</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><fpage>2730</fpage><lpage>2735</lpage><pub-id pub-id-type="doi">10.1101/gad.308904</pub-id><pub-id pub-id-type="pmid">15545631</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henshall</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Notch3 is necessary for blood vessel integrity in the central nervous system</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2015</year><volume>35</volume><fpage>409</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.304849</pub-id><pub-id pub-id-type="pmid">25477343</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Notch3 signaling promotes the development of pulmonary arterial hypertension</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><fpage>1289</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1038/nm.2021</pub-id><pub-id pub-id-type="pmid">19855400</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Kennard</surname><given-names>S</given-names></name><name><surname>Lilly</surname><given-names>B</given-names></name></person-group><article-title>NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1</article-title><source>Circ Res</source><year>2009</year><volume>104</volume><fpage>466</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.184846</pub-id><pub-id pub-id-type="pmid">19150886</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belin de Chantemele</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><fpage>2216</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.108.171751</pub-id><pub-id pub-id-type="pmid">18818417</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>EL</given-names></name><name><surname>Baker</surname><given-names>AH</given-names></name><name><surname>Bradshaw</surname><given-names>AC</given-names></name></person-group><article-title>TGFbeta, smooth muscle cells and coronary artery disease: a review</article-title><source>Cell Signal</source><year>2019</year><volume>53</volume><fpage>90</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2018.09.004</pub-id><pub-id pub-id-type="pmid">30227237</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>RY</given-names></name><name><surname>Markus</surname><given-names>HS</given-names></name></person-group><article-title>Monogenic causes of stroke: now and the future</article-title><source>J Neurol</source><year>2015</year><volume>262</volume><fpage>2601</fpage><lpage>2616</lpage><pub-id pub-id-type="doi">10.1007/s00415-015-7794-4</pub-id><pub-id pub-id-type="pmid">26037017</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>M</given-names></name><etal/></person-group><article-title>Smooth muscle 22 alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling</article-title><source>Life Sci</source><year>2009</year><volume>84</volume><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2008.11.017</pub-id><pub-id pub-id-type="pmid">19073196</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Je</surname><given-names>HD</given-names></name><name><surname>Sohn</surname><given-names>UD</given-names></name></person-group><article-title>SM22alpha is required for agonist-induced regulation of contractility: evidence from SM22alpha knockout mice</article-title><source>Mol Cells</source><year>2007</year><volume>23</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">17464194</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>1336</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1128/MCB.2001.21.4.1336-1344.2001</pub-id><pub-id pub-id-type="pmid">11158319</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joutel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><fpage>433</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1172/JCI39733</pub-id><pub-id pub-id-type="pmid">20071773</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikawati</surname><given-names>M</given-names></name><name><surname>Kawaichi</surname><given-names>M</given-names></name><name><surname>Oka</surname><given-names>C</given-names></name></person-group><article-title>Loss of HtrA1 serine protease induces synthetic modulation of aortic vascular smooth muscle cells</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><fpage>e0196628</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0196628</pub-id><pub-id pub-id-type="pmid">29768431</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubroca</surname><given-names>C</given-names></name><etal/></person-group><article-title>Impaired vascular mechanotransduction in a transgenic mouse model of CADASIL arteriopathy</article-title><source>Stroke</source><year>2005</year><volume>36</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000149949.92854.45</pub-id><pub-id pub-id-type="pmid">15569862</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname><given-names>A</given-names></name><etal/></person-group><article-title>Expression of mouse HtrA1 serine protease in normal bone and cartilage and its upregulation in joint cartilage damaged by experimental arthritis</article-title><source>Bone</source><year>2005</year><volume>37</volume><fpage>323</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2005.03.015</pub-id><pub-id pub-id-type="pmid">15993670</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>17556</fpage><lpage>17563</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.076414</pub-id><pub-id pub-id-type="pmid">20368328</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Urs</surname><given-names>S</given-names></name><name><surname>Liaw</surname><given-names>L</given-names></name></person-group><article-title>Hairy-related transcription factors inhibit Notch-induced smooth muscle alpha-actin expression by interfering with Notch intracellular domain/CBF-1 complex interaction with the CBF-1-binding site</article-title><source>Circ Res</source><year>2008</year><volume>102</volume><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.165134</pub-id><pub-id pub-id-type="pmid">18239137</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Loss of the mechanotransducer zyxin promotes a synthetic phenotype of vascular smooth muscle cells</article-title><source>J Am Heart Assoc</source><year>2015</year><volume>4</volume><fpage>e001712</fpage><pub-id pub-id-type="doi">10.1161/JAHA.114.001712</pub-id><pub-id pub-id-type="pmid">26071033</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Tetzlaff, F. <italic>et al</italic>. MPDZ promotes DLL4-induced Notch signaling during angiogenesis. <italic>Elife</italic><bold>7</bold>, 10.7554/eLife.32860 (2018).</mixed-citation></ref></ref-list></back></article>